Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iofetamine SCHEMBL29617565 | 0.98 | APEX1 (0.67) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL20862299 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL18211455 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL11151697 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL13996943 | 0.79 | CYP2D6 (0.66) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL23986761 | 0.79 | CYP1A2 (0.66) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL1534301 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL13996924 | 0.79 | CYP1A2 (0.66) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL3064259 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL10606478 | 0.79 | CYP1A2 (0.66) | CYP1A2CYP2D6APEX1PMP22SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12624020-B2 | Compositions and methods for preparing and using azetidines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-12616667-B2 | Compositions and methods for improving neurological diseases and disorders | CURASEN THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12558325-B2 | Methods for improving neurological diseases and disorders | CURASEN THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250134835-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-118335285-A | Postoperative complication prediction method, postoperative complication prediction device, terminal equipment and medium | 首都医科大学附属北京天坛医院 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024137478-A1 | METHODS FOR TREATING VARIOUS CONDITIONS AND INDICATIONS WITH AGONISTS AND ANTAGONISTS | CURASEN THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230414588-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023250334-A1 | COMPOSITIONS AND METHODS INVOLVING ISOLATED COMPOUNDS | CURASEN THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230121082-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| US-11607395-B2 | Methods for improving neurological diseases and disorders | CURASEN THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4124344-A1 | NOVEL USE OF HIC-5 INHIBITOR | Showa University (JP) | 2023-02-01 | — | — | EP | disclosed |
| US-11555082-B2 | P-boronophenylalanine derivative and composition containing same, and kit for producing said derivative and composition | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2023-01-17 | — | — | US | disclosed |
| US-11512072-B2 | Compositions and methods for preparing and using azetidines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3757137-B1 | P-BORONOPHENYLALANINE DERIVATIVE AND COMPOSITION CONTAINING SAME, AND KIT FOR PRODUCING SAID DERIVATIVE AND COMPOSITION | TOKYO INST TECH (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022051305-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555082-B2 | P-boronophenylalanine derivative and composition containing same, and kit for producing said derivative and composition | KIT, SETD7, PAH | CYP1A2 3691/4885CYP2D6 2654/4885APEX1 2660/4885 |
| US-11607395-B2 | Methods for improving neurological diseases and disorders | ADRA2A, ADRA1A, ADRA2B | CYP1A2 2333/4885CYP2D6 2854/4885APEX1 3278/4885 |
| US-11512072-B2 | Compositions and methods for preparing and using azetidines | DGKA, DGKK, PRKG2 | CYP1A2 2261/4885CYP2D6 1012/4885APEX1 3087/4885 |
| US-12558325-B2 | Methods for improving neurological diseases and disorders | ADRB2, ADRB1, ADRA1B | CYP1A2 1554/4885CYP2D6 2911/4885APEX1 3192/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | CYP1A2 3241/4885CYP2D6 2536/4885APEX1 2958/4885 |
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | CYP1A2 912/4885CYP2D6 966/4885APEX1 461/4885 |
| US-12616667-B2 | Compositions and methods for improving neurological diseases and disorders | ADRB2, ADRB1, ADRA2A | CYP1A2 1377/4885CYP2D6 1587/4885APEX1 3723/4885 |
| US-20250134835-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | SMN1; SMN2, HNRNPU, ADRB1 | CYP1A2 3912/4885CYP2D6 4266/4885APEX1 4118/4885 |
| US-12624020-B2 | Compositions and methods for preparing and using azetidines | PRKAR2A, GRK2, GRK6 | CYP1A2 2660/4885CYP2D6 723/4885APEX1 3143/4885 |
| US-20230414588-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | SMN1; SMN2, HNRNPU, ADRB1 | CYP1A2 3912/4885CYP2D6 4266/4885APEX1 4118/4885 |
| US-20230121082-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES | DGKA, DGKK, PRKG2 | CYP1A2 2261/4885CYP2D6 1012/4885APEX1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.